INSM: The Re-Estimate Heard 'Round the Street

Insmed more than doubles its peak sales estimates after a historic BRINSUPRI quarter and compelling TPIP data.

INSM · Earnings Call · 2026-08-06

A Quarter That Rewrote the Model

Insmed delivered a Q2 that fundamentally changes the narrative. BRINSUPRI, the once-daily DPP1 inhibitor for bronchiectasis, booked $309.2 million in its third full quarter—more than double the best comparable specialty respiratory launch ever. The company raised full-year guidance to $1.25–1.4 billion and, more strikingly, peak sales estimates for the lead asset jumped to >$7 billion from >$5 billion. As CEO Will Lewis put it: “BRINSUPRI's launch continues at a truly historic pace, delivering another quarter of performance that more than doubled the results of the best specialty respiratory launches our industry has ever seen at this stage.” — William Lewis, Chief Executive Officer · 2026-08-06 The guidance hike is backed by operational strength: ~7,000 new patient starts in Q2, all organic—“It is 100% organic demand. Ready and waiting patients are gone.” — William Lewis, Chief Executive Officer · 2026-08-06 Cumulative prescribers topped 6,300, and depth is building: 30% of writers now have five or more patients. Persistence and compliance are tracking at or above internal benchmarks, a critical variable for a launch's durability.

TPIP and the Second Megablockbuster

The open label extension data for TPIP in PAH are nothing short of transformative. Twelve-month results showed a 55-meter improvement in 6-minute walk distance, a 60% reduction in NT-proBNP, and 80% of patients achieving functional class I/II. Crucially, placebo crossovers fully caught up—a phenomenon rarely observed. Peak sales for TPIP are now estimated above $6 billion (up from >$2 billion), assuming success across all four indications. Lewis stated:

we assume that we will be approved in all 4 of the indications, PAH, PH-ILD, IPF and PPF. We assume we do overcome the orphan status for IPF. And we assume that we have a profile that is not only clearly superior to other prostanoids but is comparable to sotatercept.
Leonid Timashev, Analyst · 2026-08-06

This is a sea change from the cautious tone of just a quarter ago. In May, Lewis demurred: “there may be a time when we want to come back and explore what those peak numbers are. I just think after 1 quarter in the year, the calendar year, it's a little premature.” — William Lewis, Chief Executive Officer · 2026-05-07 The contrast is stark—and telling.

Financial Runway and Strategic Optionality

With ~$1.2 billion in cash at quarter-end, the company sees a clear path to cash-flow positivity in 2027 without raising equity—a stance echoed from February: “we see a very clear path to cash flow positivity.” — William H. Lewis, Chief Executive Officer · 2026-02-19 The fundamentals corroborate improving economics: Effective Net Cash stood near $1.3B as of the last filing, even before this quarter's revenue surge. The pipeline extends beyond respiratory. The FDA cleared the IND for INS-1033, a next-generation DPP1 inhibitor targeting rheumatoid arthritis, ulcerative colitis, and COPD. EMBARC will run a 3,000-patient study in Europe. And the company is aggressively pursuing earlier diagnosis of bronchiectasis in comorbid COPD/asthma populations—an upside not yet reflected in the MAC lung disease numbers (ARIKAYCE's label expansion adds yet another catalyst). This is a company in a new phase: not a one-drug bet, but a portfolio firing on multiple cylinders. Yet the stock has pulled back 18.8% from its April peak, suggesting the market is still digesting the magnitude—or questioning the achievability of the peak assumptions. With combined >$14B in peak sales estimates across three assets, Insmed is now in the rarefied air of multi-blockbuster specialty pharma. Whether the re-estimate holds will depend on execution, but the trajectory is undeniably momentum.